Janux Therapeutics, Inc. (NASDAQ:JANX) Insider Sells $731,769.92 in Stock

Janux Therapeutics, Inc. (NASDAQ:JANX) insider Andrew Hollman Meyer sold 13,334 shares of the stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $54.88, for a total value of $731,769.92. Following the transaction, the insider now directly owns 82,139 shares of the company’s stock, valued at approximately $4,507,788.32. This trade represents a 13.97 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Janux Therapeutics Stock Performance

Janux Therapeutics stock opened at $53.92 on Monday. The stock has a market cap of $2.83 billion, a P/E ratio of -46.09 and a beta of 3.29. Janux Therapeutics, Inc. has a fifty-two week low of $7.79 and a fifty-two week high of $71.71. The firm’s fifty day moving average price is $54.53 and its 200-day moving average price is $47.93.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.18). Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. The business had revenue of $0.44 million during the quarter, compared to analysts’ expectations of $1.50 million. The firm’s quarterly revenue was down 82.6% on a year-over-year basis. Sell-side analysts predict that Janux Therapeutics, Inc. will post -1.35 earnings per share for the current year.

Institutional Investors Weigh In On Janux Therapeutics

Several hedge funds have recently bought and sold shares of JANX. Plato Investment Management Ltd increased its holdings in shares of Janux Therapeutics by 18.7% in the 3rd quarter. Plato Investment Management Ltd now owns 1,186 shares of the company’s stock worth $54,000 after buying an additional 187 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in Janux Therapeutics by 21.9% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock worth $87,000 after acquiring an additional 339 shares in the last quarter. Amalgamated Bank increased its stake in Janux Therapeutics by 61.1% in the second quarter. Amalgamated Bank now owns 970 shares of the company’s stock valued at $41,000 after acquiring an additional 368 shares during the last quarter. Virtu Financial LLC increased its stake in Janux Therapeutics by 48.0% in the third quarter. Virtu Financial LLC now owns 7,463 shares of the company’s stock valued at $339,000 after acquiring an additional 2,419 shares during the last quarter. Finally, Zacks Investment Management raised its position in Janux Therapeutics by 8.7% during the third quarter. Zacks Investment Management now owns 42,133 shares of the company’s stock valued at $1,914,000 after purchasing an additional 3,360 shares in the last quarter. 75.39% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $200.00 price target on shares of Janux Therapeutics in a research report on Wednesday, December 11th. Stifel Nicolaus increased their target price on shares of Janux Therapeutics from $70.00 to $115.00 and gave the stock a “buy” rating in a research report on Tuesday, December 3rd. Leerink Partnrs raised shares of Janux Therapeutics to a “strong-buy” rating in a research report on Friday, November 22nd. UBS Group started coverage on shares of Janux Therapeutics in a research note on Thursday, October 24th. They set a “buy” rating and a $69.00 price target on the stock. Finally, BTIG Research lifted their price objective on shares of Janux Therapeutics from $82.00 to $100.00 and gave the company a “buy” rating in a research note on Tuesday, December 3rd. One research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, Janux Therapeutics presently has an average rating of “Buy” and an average price target of $89.90.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.